PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: PF-06882961 Immediate Release Tablet
Drug: PF-06882961 Controlled Release Tablet (long)
Drug: PF-06882961 Controlled Release Tablet (short)
Drug: PF-06882961 Immediate Release Solution

First Posted Date: 2018-04-10

Last Posted Date: 2018-07-30

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT03492697

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Anaemetro I.V. Infusion 500mg Drug Use Investigation

Completed

Conditions: Anaerobic Infection
Infectious Enterocolitis
Amebic Dysentery

First Posted Date: 2018-04-09

Last Posted Date: 2018-12-28

Lead Sponsor: Pfizer

Target Recruit Count: 107

Registration Number: NCT03491228

Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Other: Placebo
Drug: Tofacitinib

First Posted Date: 2018-04-03

Last Posted Date: 2024-02-08

Lead Sponsor: Pfizer

Target Recruit Count: 204

Registration Number: NCT03486457

Locations: 🇨🇳
The Third Hospital of Hebei Medical University, Rheumatology and Immunology Department, Shijiazhuang, Hebei, China
🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

and more 35 locations

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Phase 2

Terminated

Conditions: Urothelial Cancer
Non-Small Cell Lung Cancer

Interventions: Drug: Avelumab (MSB0010718C)
Drug: Axitinib (AG-013736)

First Posted Date: 2018-03-21

Last Posted Date: 2024-04-09

Lead Sponsor: Pfizer

Target Recruit Count: 61

Registration Number: NCT03472560

Locations: 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
🇨🇳
Chi Mei Hospital, Liouying, Tainan City, Liouying District, Taiwan

and more 31 locations

Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: PF-06763809
Other: Vehicle
Drug: Calcipotriene/calcipotriol
Drug: Betamethasone

First Posted Date: 2018-03-19

Last Posted Date: 2020-06-25

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT03469336

Locations: 🇩🇪
bioskin GmbH, Hamburg, Germany
🇩🇪
Rothaar Studien GmbH, Berlin, Germany

Trial in Adult Subjects With Acute Migraines

Phase 3

Completed

Conditions: Migraine, With or Without Aura

Interventions: Drug: Placebo
Drug: Rimegepant

First Posted Date: 2018-03-12

Last Posted Date: 2023-02-16

Lead Sponsor: Pfizer

Target Recruit Count: 1811

Registration Number: NCT03461757

Locations: 🇺🇸
Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States
🇺🇸
Sundance Clinical Research, Saint Louis, Missouri, United States
🇺🇸
Ki Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut, United States

and more 60 locations

Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Phase 1

Recruiting

Conditions: Follicular Lymphoma (FL)
Small Cell Lung Cancer (SCLC)
Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions: Drug: Mervometostat (PF-06821497)
Drug: Enzalutamide

First Posted Date: 2018-03-09

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 343

Registration Number: NCT03460977

Locations: 🇺🇸
Urological Associates of Southern Arizona, P.C ., Tucson, Arizona, United States
🇺🇸
Banner-University Medical Center Tucson, Tucson, Arizona, United States
🇺🇸
The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

and more 82 locations

A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

Phase 2

Terminated

Conditions: Focal Segmental Glomerulosclerosis (FSGS)

Interventions: Drug: PF-06730512

First Posted Date: 2018-02-28

Last Posted Date: 2024-04-18

Lead Sponsor: Pfizer

Target Recruit Count: 47

Registration Number: NCT03448692

Locations: 🇺🇸
The Cleveland Clinic - Investigational Drug Pharmacy, Cleveland, Ohio, United States
🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
The Kirklin Clinic of University Alabama Birmingham Hospital, Birmingham, Alabama, United States

and more 104 locations

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]PF-05221304

First Posted Date: 2018-02-27

Last Posted Date: 2018-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT03448172

Locations: 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States

Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®

Recruiting

Conditions: Breast Neoplasm

First Posted Date: 2018-02-26

Last Posted Date: 2024-08-28

Lead Sponsor: Pfizer

Target Recruit Count: 540

Registration Number: NCT03445637

Locations: 🇰🇷
Pfizer Tower, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy